Professor Jones will lead the development of protein footprinting technology to study protein interactions of in vivo membrane proteins.

HALF MOON BAY, Calif. – January 11, 2023 – With ambitious plans to expand the reach and impact of their Flash Oxidation (Fox™) Protein Footprinting System beyond in vitro proteins, GenNext Technologies, Inc. (GenNext) is adding to the strength of their leadership team with the selection of Dr. Lisa Jones as the company’s new CSO. Transitioning from her role on the company’s Scientific Advisory Board, GenNext will benefit from Dr. Jones’ experience as the world-recognized pioneer of in-cell and whole-organism Fast Photochemical Oxidation of Proteins (FPOP).

Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise.

Half Moon Bay, CA. – January 10, 2023 – GenNext Technologies, Inc., an innovative provider of laboratory tools for advanced structural characterization of proteins, announced today that Dr. John L. Grant has joined its Board of Directors.

Dr. Grant served as a highly valuable mentor for GenNext during the BioTools Innovation 2022 Cohort Program where the company was selected as the Grand Prize Winner. During this intensive collaboration, Dr. Grant gained exposure to the GenNext team and technology, ultimately deciding to take on a more formal role as an advisor on the BOD.

Company will use the award to further develop scientific instruments, software, and services that ultimately improve the safety, stability, and effectiveness of biotherapeutics.

HALF MOON BAY, Calif. – October 26, 2022 – GenNext Technologies, Inc., a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers, today announced that it received the 2022 Grand Prize Award in the BioTools Innovator competition.

BioTools Innovator is the largest life science accelerator in the world, supported by founding partners Research Corporation Technologies and BroadOak Capital Partners. GenNext, chosen amongst a field of 160 emerging life science tools companies, will receive $250K in non-dilutive funding, along with access to an elite ecosystem of mentors, peers, and investors to help ensure the continued growth of GenNext Technologies and the success of its customers in biopharmaceutical discovery and development.

Kiko Tech is a premier distributor of state-of-the-art instruments and reagents for molecular diagnostics, proteomics, applied testing, pharmaceutical, and academic research since its establishment in 1974. The Kiko Tech team is excited about the opportunity to introduce the Japanese scientific community to the novel Fox™-based approach to Hydroxyl Radical Protein Footprinting (HRPF).

​HALF MOON BAY, Calif. – May 11, 2022 – GenNext Technologies, Inc. (GenNext), announced today a partnership with Kiko Tech Co., Ltd., to provide Flash Oxidation (Fox™) Protein Footprinting Systems to the Japanese life science research market.

Under an agreement between the parties, Kiko Tech has been appointed sole distributor for the GenNext product portfolio for Japan. Together, GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation (Fox™) Protein Footprinting Systems.

GenNext will use this award to advance its intellectual property and expertise to develop a fully automated platform that will study drug-induced HOS structure changes within living cells, with its first system designed for in-vivo protein footprinting studies.

HALF MOON BAY, Calif. – March 24, 2022 – GenNext Technologies, Inc., a growth-stage company providing biopharmaceutical drug discovery systems and services, announced today the receipt of a two-year, Phase II SBIR grant for a project titled “In-Cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System.” The grant was awarded by the National Institute of General Medical Systems (NIGMS) of the U.S. Department of Health and Human Services. The purpose of the grant is to extend GenNext’s breakthrough Hydroxyl Radical Protein Footprinting (HRPF) technology and methods to studies involving living cells.

The United States Patent and Trademark Office (USPTO) has issued GenNext a Patent for Radical Dosimetry for the Analysis of Biopharmaceuticals and Biological Molecules.

HALF MOON BAY, Calif. – December 9, 2021 – GenNext Technologies, Inc., a growth-stage company providing instrumentation, software, and services, announced today that it has earned a second seminal patent protecting the company’s novel radical dosimetry technology which vastly improves the utility of protein footprinting for the study of biopharmaceutical structure, function, and safety.

The United States Patent and Trademark Office (USPTO) has issued Patent US 11,181,529 B2: “Radical Dosimetry for the Analysis of Biopharmaceuticals and Biological Molecules.” This patent protects the company’s novel core technology and Intellectual Property (IP) that enables real-time assessment of protein footprinting chemical reactions with robust accuracy and reproducibility, while substantially improving ease-of-use.